Share on StockTwits

Ovascience (NASDAQ:OVAS) Director Richard Aldrich bought 2,000 shares of Ovascience stock in a transaction that occurred on Monday, June 2nd. The stock was purchased at an average price of $7.29 per share, with a total value of $14,580.00. Following the completion of the transaction, the director now directly owns 526,445 shares of the company’s stock, valued at approximately $3,837,784. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on OVAS shares. Analysts at HC Wainwright reiterated a “buy” rating on shares of Ovascience in a research note on Monday, May 12th. Separately, analysts at Oppenheimer initiated coverage on shares of Ovascience in a research note on Tuesday, April 29th. They set an “outperform” rating and a $11.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Ovascience to $16.00 in a research note on Thursday, April 3rd.

Shares of Ovascience (NASDAQ:OVAS) traded down 1.66% on Wednesday, hitting $7.11. 3,600 shares of the company’s stock traded hands. Ovascience has a one year low of $5.509 and a one year high of $16.00. The stock’s 50-day moving average is $7.52 and its 200-day moving average is $8.96. The company’s market cap is $166.0 million.

Ovascience (NASDAQ:OVAS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.05. On average, analysts predict that Ovascience will post $-1.92 earnings per share for the current fiscal year.

OvaScience, Inc, is a life science company developing products to improve the treatment of female infertility based on recent scientific discoveries about the existence of egg precursor cells.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.